Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 4/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660132 | 1.00 | MTNR1B (0.57) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL28471149 | 0.98 | MTNR1B (0.55) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL2090211 | 0.85 | MTNR1B (0.62) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL7785497 | 0.84 | MTNR1B (0.51) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL11114174 | 0.84 | MTNR1A (0.66) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL12520413 | 0.83 | MTNR1B (0.60) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL12246651 | 0.82 | MTNR1A (0.59) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL10201679 | 0.82 | MEN1 (0.56) | MTNR1BMTNR1AMEN1KMT2AMAPT | |
| SCHEMBL146848 | 0.82 | TP53 (0.53) | MEN1KMT2AMAPTMAPK1ALDH1A1 | |
| 1-Hydroxy-3-Methoxybenzene SCHEMBL9774366 | 0.82 | MEN1 (0.50) | MTNR1BMTNR1AMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-12-25 | — | — | US | claimed |
| CN-115925626-B | Novel aporphine compound and preparation method and application thereof | 中国药科大学 | 2025-06-13 | — | — | CN | claimed |
| EP-4565233-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | Zydus Lifesciences Limited (IN) | 2025-06-11 | — | — | EP | claimed |
| EP-4539934-A1 | TREATMENT FOR GLOMERULAR DISEASES | Zydus Lifesciences Limited (IN) | 2025-04-23 | — | — | EP | claimed |
| CN-118420612-A | Target protein degradation compound based on CDK4/6 inhibitor and preparation method and application thereof | 沈阳药科大学 | 2024-08-02 | — | — | CN | claimed |
| CN-115894365-B | Synthesis method of tetrahydroisoquinoline compound and intermediate thereof | 南方科技大学坪山生物医药研究院 | 2024-07-02 | — | — | CN | claimed |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | ZYDUS LIFESCIENCES LTD. (IN) | 2024-05-30 | — | — | US | claimed |
| CN-117560937-A | Perovskite solar cell based on 3-methoxy phenethylamine passivating agent and preparation method thereof | 常州大学 | 2024-02-13 | — | — | CN | claimed |
| WO-2024028744-A1 | TREATMENT FOR APLASTIC ANEMIA (AA) | ZYDUS LIFESCIENCES LIMITED (IN) | 2024-02-08 | — | — | WO | claimed |
| EP-4308120-A1 | TREATMENT FOR SICKLE CELL ANAEMIA | Zydus Lifesciences Limited (IN) | 2024-01-24 | — | — | EP | claimed |
| WO-2015001573-A9 | SYNERGISTIC COMPOSITIONS | CADILA HEALTHCARE LIMITED (IN) | 2016-02-25 | — | — | WO | claimed |
| CN-105358145-A | Synergistic compositions | CADILA HEALTHCARE LTD | 2016-02-24 | — | — | CN | claimed |
| US-9249091-B2 | Post-treated sulfurized salt of an alkyl-substituted hydroxyaromatic composition | CHEVRON ORONITE COMPANY LLC (US) | 2016-02-02 | — | — | US | claimed |
| WO-2015001573-A1 | SYNERGISTIC COMPOSITIONS | CADILA HEALTHCARE LIMITED (IN) | 2015-01-08 | — | — | WO | claimed |
| EP-2451786-B1 | IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | CADILA HEALTHCARE LTD (IN) | 2014-01-22 | — | — | EP | claimed |
| CN-102285904-B | Method for preparing rivastigmine | CHENGDU INST BIOLOGY CAS | 2013-06-05 | — | — | CN | claimed |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2012-07-19 | — | — | US | claimed |
| EP-2451786-A2 | IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-05-16 | — | — | EP | claimed |
| CN-102285904-A | Method for preparing rivastigmine | — | 2011-12-21 | — | — | CN | claimed |
| EP-0474200-B1 | Process for the resolution of racemic 2,2-dimethyl cyclopropane carboxylic acid | LONZA AG (CH) | 1994-12-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387385-A1 | TREATMENT FOR GLOMERULAR DISEASES | SSB, GRN, ALB | MTNR1B 1730/4885MTNR1A 1249/4885MEN1 1156/4885 |
| US-20120184573-A1 | PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF | ACVR1, ACVR1B, CYP11B1 | MTNR1B 107/4885MTNR1A 271/4885MEN1 191/4885 |
| US-20240173314-A1 | TREATMENT OF SICKLE CELL ANAEMIA | HBG1, HBB, HBG2 | MTNR1B 3479/4885MTNR1A 4260/4885MEN1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.